Loading data for CING — first visit, this takes a few seconds.
Cingulate Inc. (CING)
NasdaqCM: CING
· Echtzeitkurs · USD
5.27
+0.07 (1.35%)
Zum Schluss: Aug 20, 2026, 3:59 PM
Cingulate Inc. (CING) Stock Price, Analysis & Data
1.35% (1D)
| Geld | 5.24 |
| Marktkapitalisierung | 75.62 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -28.81 Mio |
| Beta | -0.91 |
| EPS (ttm) | -3.56 |
| KGV (TTM) | n/a |
| Forward-KGV | -5.47 |
| KBV (TTM) | 15.03 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | 6.5 |
| Volumen | 162,098 |
| Ø Vol. (20D) | 429,253 |
| Eröffnung | 5.15 |
| Vortagesschluss | 5.20 |
| Tagesspanne | 5.01 - 5.29 |
| 52-Wk Range | 3.16 - 11.89 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a f...
Branche Biotechnology
Sektor Healthcare
IPO Datum Dec 8, 2021
Mitarbeiter 14
Börse NasdaqCM
Tickersymbol CING
Website https://www.cingulate.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Cingulate 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -22.45 Mio, ein Anstieg von 35.57 %.
FinanzberichteGewinnüberraschung
Cingulate hat die Quartalszahlen am Aug 13, 2026 veröffentlicht:
